CANVAS : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

CANVAS : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

• FDA approved for reduction of cardiac mortality in adults with T2DM and established CVD.

• Canagliflozin is a suggested add-on therapy to metformin for patients with T2DM patients with established CVD (AACE 2019).

Infographic

Reference

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657.

>